Evidence map›Paper›PMID 36203546›Full record

ArticlebioRxiv : the preprint server for biology2022

SARS-CoV-2 Uses Nonstructural Protein 16 to Evade Restriction by IFIT1 and IFIT3.

Craig Schindewolf, Kumari Lokugamage, Michelle N Vu, Bryan A Johnson, Dionna Scharton, Jessica A Plante, Birte Kalveram, Patricia A Crocquet-Valdes, Stephanea Sotcheff, Elizabeth Jaworski and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 9 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Craig SchindewolfDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Kumari LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Michelle N VuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Bryan A JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Dionna SchartonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Birte KalveramDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Patricia A Crocquet-ValdesDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Stephanea SotcheffDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
Elizabeth JaworskiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.
R Elias AlvaradoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Kari DebbinkDepartment of Microbiology and Immunology, Johns Hopkins University, Baltimore, MD, USA.
Matthew D DaughertyDepartment of Molecular Biology, University of California, San Diego, CA, USA.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Andrew L RouthInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.
David H WalkerDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · USJohns Hopkins University · USUniversity of California San Diego · US

Funding

Virology CoreU19AI171413 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SARKO, CHRISTOPHER · 2022 to 2023
$75.0M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
EMERGING AND TROPICAL INFECTIOUS DISEASEST32AI007526 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SOONG, LYNN · 1997 to 2025
$3.1M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
NIAID NIH HHS R01 AI153602NIAID NIH HHS R21 AI145400NIAID NIH HHS R24 AI120942NIAID NIH HHS T32 AI007526NIAID NIH HHS T32 AI060549NIAID NIH HHS U19 AI171413
6 · The paper itself

Abstract

Understanding the molecular basis of innate immune evasion by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important consideration for designing the next wave of therapeutics. Here, we investigate the role of the nonstructural protein 16 (NSP16) of SARS-CoV-2 in infection and pathogenesis. NSP16, a ribonucleoside 2'- Importance: Similar to other coronaviruses, disruption of SARS-CoV-2 NSP16 function attenuates viral replication in a type I interferon-dependent manner.

Identifiers

PMID36203546
PMCPMC9536030
OpenAlexW4297399661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.